Argininosuccinic Aciduria Clinical Trials

Find Argininosuccinic Aciduria Clinical Trials Near You

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Adult male or female participants, 18 to 65 years of age

• Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and screening laboratory assessments, in the opinion of the Investigator.

• Female participant of childbearing potential or male participant that is willing to use an approved, reliable means of contraception

• Willing and able to provide signed written informed consent and to comply with all study requirements

Locations
Other Locations
Australia
Nucleus Network Pty Ltd
RECRUITING
Melbourne
Contact Information
Primary
Nucleus Network Pty Ltd Study Director
name@name.com
(03) 8593 9801
Time Frame
Start Date: 2026-09-28
Estimated Completion Date: 2027-09
Participants
Target number of participants: 30
Treatments
Experimental: KRRO-121
KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide that recruits endogenous hepatic ADAR to edit mRNA, producing a de novo glutamine synthetase (GS) protein resistant to feedback-driven proteasomal degradation. By stabilizing hepatic GS, KRRO-121 augments ammonia clearance capacity independently of the underlying urea cycle enzyme defect.
Placebo_comparator: Placebo
Placebo
Sponsors
Leads: Korro Bio, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials